81 results
8-K
EX-99.1
FUSN
Fusion Pharmaceuticals Inc
7 May 24
Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates
7:30am
. The development plan includes a Phase 2 dose optimization lead-in, which
aims to evaluate whether there are added safety and/or efficacy benefits … of its ongoing Phase 1, multi-center, open-label clinical trial. The trial is designed to investigate the safety, tolerability, and pharmacokinetics
DEFM14A
FUSN
Fusion Pharmaceuticals Inc
25 Apr 24
Proxy related to merger
4:13pm
;
the risk that adverse side effects or other safety risks associated with FPI-2265 or Fusion’s other product candidates could delay or preclude approval … , in each case, if related to safety), any product or product candidate competitive with any of Fusion’s products or product candidates (including (1
8-K/A
FUSN
Fusion Pharmaceuticals Inc
12 Apr 24
Other Events
5:02pm
at the American Association for Cancer Research Annual Meeting 2024 (the “Original AACR Poster”), which showed interim efficacy and safety data from
PREM14A
dih087f1qf
10 Apr 24
Preliminary proxy related to merger
4:42pm
8-K
0c0grhmd4gh1eul
9 Apr 24
Other Events
4:10pm
8-K
EX-99.1
cstlzd81ra yama
20 Mar 24
Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates
4:10pm
DEFA14A
wz4m895
19 Mar 24
Additional proxy soliciting materials
6:25am
8-K
EX-2.1
vw51vg
19 Mar 24
Voting and Support Agreement
6:24am
8-K
EX-10.1
qikgc0kx2
16 Feb 24
Entry into a Material Definitive Agreement
4:05pm
424B5
ec0drl
19 Jan 24
Prospectus supplement for primary offering
4:10pm
8-K
EX-99.2
l4crqh1n5dapjb
4 Jan 24
Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates
4:31pm
8-K
yl9a8
4 Jan 24
Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates
4:31pm
8-K
EX-99.1
mu09q72ft
4 Jan 24
Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates
4:31pm
8-K
EX-99.1
ugnby
7 Nov 23
Fusion Pharmaceuticals Announces Third Quarter 2023 Financial Results and Clinical Program Updates
7:45am
8-K
EX-99.1
0jzz3 fx8yxg
8 Aug 23
Fusion Pharmaceuticals Announces Second Quarter 2023 Financial Results and Clinical Program Updates
7:30am